DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed the authors developed a sophisticated liposome conjugated with Begelomab (anti-CD26) loaded with venetoclax to target CD26+ CML LSCs/progenitor cells selectively.